Contribution: Industrial Research Assistance Program – Contributions to Firms
AffinityImmuno Inc.
$250,000.00
Covid 19 diagnostic
FY 2020-21 · 2020-04-01
Summary
A major roadblock in COVID-19 research is the lack of available reagents for research and manufacturing. The need for research reagents is urgent. AffinityImmuno has developed a very rapid turnaround immunization protocol and has the first available antibodies on the market.
AffinityImmuno has raised antibodies against the full extracellular domain of COVID-19 spike protein and nucleocapsid and has the opportunity to develop critical components that will be used in R&D of diagnostic products and products that will affect the disease course. Because the antibodies were raised in chicken we have a large supply and are now working towards developing critical products in partnership with the private sector and academia.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Brackley|Brackley, Prince Edward Island, Canada
Recipient Type
For-profit organization
Business Number
807019971
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2020-04-01 | 2020-21 | $200,000.00 |
| 2 | 2020-04-01 | 2020-21 | $200,000.00 |
| 3 | 2020-04-01 | 2020-21 | $250,000.00 |
| 4 | 2020-04-01 | 2020-21 | $250,000.00 |
As published
Additional Information
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 184 days.
Additional Information (French)
Cet accord a été modifié 1 fois La date de fin du présent accord a été changé de 184 jours.
Agreement End Date
2022-08-31
Agreement Number
947829
Agreement Start Date
2020-04-01
Agreement Title
Covid 19 diagnostic
Agreement Title (French)
Diagnostic de la Covid-19
Agreement Type
Contribution
Agreement Value
$250,000.00
Amendment Date
2022-03-16
Amendment Number
4
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
A major roadblock in COVID-19 research is the lack of available reagents for research and manufacturing. The need for research reagents is urgent. AffinityImmuno has developed a very rapid turnaround immunization protocol and has the first available antibodies on the market.
AffinityImmuno has raised antibodies against the full extracellular domain of COVID-19 spike protein and nucleocapsid and has the opportunity to develop critical components that will be used in R&D of diagnostic products and products that will affect the disease course. Because the antibodies were raised in chicken we have a large supply and are now working towards developing critical products in partnership with the private sector and academia.
Description (French)
Un obstacle majeur à la recherche sur la COVID-19 est le manque de réactifs disponibles pour la recherche et la fabrication. Le besoin de réactifs pour la recherche est urgent. AffinityImmuno a mis au point un protocole d'immunisation à délai très court et dispose des premiers anticorps disponibles sur le marché. AffinityImmuno a produit des anticorps contre l'ensemble du domaine extracellulaire de la protéine de spicule COVID-19 et de la nucléocapside et a la possibilité de développer des composants essentiels qui seront utilisés dans la R-D de produits de diagnostic et de produits qui affecteront l'évolution de la maladie. Comme les anticorps ont été élevés dans des poulets, nous disposons d'une réserve importante et nous travaillons maintenant au développement de produits critiques en partenariat avec le secteur privé et les universités.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Malpeque
Federal Riding (French)
Malpeque
Federal Riding Number
11004
NAICS Code
541710
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
807019971
Recipient City
Brackley|Brackley
Recipient Country
CA
Recipient Legal Name
AffinityImmuno Inc.
Recipient Postal Code
C1E 1C4
Recipient Province or Territory
PE
Recipient Type
F
Reference Number
172-2020-2021-Q1-947829
